Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Basit Öğe Kaydı
dc.contributor.authorAkyıldız, Arif
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorKöksal, Barış
dc.contributor.authorKaraoğlan, Beliz Bahar
dc.contributor.authorKıvrak, Derya
dc.contributor.authorIsmayilov, Rashad
dc.contributor.authorAslan, Fırat
dc.contributor.authorSütçüoğlu, Osman
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorKadıoğlu, Ahmet
dc.contributor.authorAlan, Özkan
dc.contributor.authorMajidova, Nargiz
dc.contributor.authorErciyestepe, Mert
dc.contributor.authorÖzcan, Erkan
dc.contributor.authorAkdağ, Goncagül
dc.contributor.authorTaban, Hakan
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorGuliyev, Murad
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorSakalar, Teoman
dc.contributor.authorYazılıtaş, Doğan
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorOn, Sercan
dc.contributor.authorBiter, Sedat
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorŞenler, Filiz Çay
dc.contributor.authorKemal, Yasemin
dc.contributor.authorHalil, Ömer Diker
dc.contributor.authorGüllü, İbrahim
dc.contributor.authorAksoy, Sercan
dc.date.accessioned2024-05-28T07:35:33Z
dc.date.available2024-05-28T07:35:33Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjectives: Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial. This study aimed to evaluate the real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. Design: In this multicenter retrospective study, we analyzed 124 patients with recurrent or metastatic non-nasopharyngeal HNC who received nivolumab in the second-line setting and beyond. Data were collected from 20 different cancer centers across Turkey. The effectiveness and safety of the treatment and survival outcomes were evaluated. Results: Nivolumab exhibited favorable clinical responses, yielding an objective response rate of 29.9% and a disease control rate of 55.7%. Safety assessments revealed a generally well-tolerated profile, with no instances of treatment discontinuation or mortality due to side effects. Survival analysis disclosed a median overall survival (OS) of 11.8 (95% CI 8.4-15.2) months. Multivariate analysis revealed that ECOG-PS ≥ 1 (HR: 1.64, p = 0.045), laryngeal location (HR: 0.531, p = 0.024), and neutrophil-to-lymphocyte ratio > 3.5 (HR: 1.97, p = 0.007) were independent predictors of OS. Conclusions: Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes.en_US
dc.identifier.citationAkyıldız, A., Güven, D. C., Köksal, B., Karaoğlan, B. B., Kıvrak, D., Ismayilov, R., Aslan, F., Sütçüoğlu, O., Yazıcı, O., Kadıoğlu, A., Alan, Ö., Majidovs, N., Erciyestepe, M., Özcan, E., Akdağ, G., Taban, H., Kaya, A. O., Guliyev, M., Yıldırım, N., Sakalar, T., Yazılıtaş, D., Ünal, Ç., On, S., Biter, S., Demirci, N. S., Şenler, F. Ç., Kemal, Y., Halil, Ö. D., Güllü, İ., Aksoy, S. (2024). Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG). European Archives of Oto-Rhino-Laryngology, 281(9), 4991-4999. 10.1007/s00405-024-08744-4en_US
dc.identifier.endpage4999en_US
dc.identifier.issn0937-4477
dc.identifier.issn1434-4726
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-85194398073
dc.identifier.scopusqualityQ1
dc.identifier.startpage4991en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4710
dc.identifier.volume281en_US
dc.identifier.wosWOS:001234603400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKemal, Yasemin
dc.language.isoen
dc.relation.ispartofEuropean Archives of Oto-Rhino-Laryngology
dc.relation.isversionof10.1007/s00405-024-08744-4en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHead and neck canceren_US
dc.subjectNivolumaben_US
dc.titleReal-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
s00405-024-08744-4.pdf
Boyut:
926.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu